Transcripta Bio operates a closed-loop discovery engine that uses transcriptomic signature matching to find drug candidates whose molecular signatures invert patient-derived disease signatures. Its platform comprises a Disease Signature Atlas built from patient single-cell RNA sequencing data, a Drug-Gene Atlas mapping transcriptomic responses of compounds, and Conductor AI, a machine learning system trained on more than one billion gene responses. The company’s pipeline spans four programs across Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), Autism Spectrum Disorder (ASD), and Huntington’s Disease (HD). Transcripta is advancing IND-enabling studies and preparing clinical work for its ASD and FSHD programs. The company is based in Palo Alto, California. It has raised $24 million since its Series A to accelerate progression of its pipeline toward human clinical trials.

Total raised

$34M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2026